搜尋結果
04 主席報告書 阿里健康信息技術有限公司 二零二二年年報 憑藉互聯網科技與數字技術領域的優勢，以及深耕多年的品牌優勢與資源，阿里健康在醫生、藥企商家及患者用戶間 構築起解決供需關係的關鍵橋樑，打造出線上線下一體化的醫藥健康品服務平台，並不斷提升用戶體驗。
03 阿里健康信息技術有限公司 二零二一年年報 主席報告書 致尊敬的各位股東： 2020年，注定被重重的寫入人類歷史。這一年，突如其來的新冠疫情引發全球性危機，全人類對公共 衞生和健康安全 的重視隨著疫情的反復被深深刻入人類社會的基因。這一年，人們對病毒防範的意識逐步增強，醫療 ...
- Independent Non-executive Directors
- Audit Committee
- Remuneration Committee
- Nomination Committee
- AUDITOR
- PRINCIPAL BANKERS
- COMPANY WEBSITE
- MANAGEMENT DISCUSSION AND ANALYSIS (CONTINUED)
- • Digital Tracking Business
- Public Service
- Future Prospects
- Liquidity
- Foreign exchange exposures
- DIRECTORS
- Executive Directors:
- Independent Non-executive Directors:
- Name of Director
- PURCHASE, REDEMPTION OR SALE OF THE COMPANY’S LISTED SECURITIES
- MODEL CODE FOR SECURITIES TRANSACTIONS
- (b) Non-current assets
- Other income
- Gains
- 8. PROFIT/(LOSS) BEFORE TAX
- Earnings/(loss)
- (I) Transactions with related parties
- Outstanding balances with related parties:
- 18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
- Financial assets
- 18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)
- Fair value hierarchy
Mr. LUO Tong Mr. WONG King On, Samuel Ms. HUANG Yi Fei (Vanessa)
Mr. WONG King On, Samuel (Chairman) Mr. LUO Tong Ms. HUANG Yi Fei (Vanessa)
Ms. HUANG Yi Fei (Vanessa) (Chairman) Mr. LI Faguang Mr. WONG King On, Samuel
Mr. ZHU Shunyan (Chairman) Mr. LUO Tong Mr. WONG King On, Samuel
Ernst & Young Certified Public Accountants Registered Public Interest Entity Auditor
China CITIC Bank International Limited The Hongkong and Shanghai Banking Corporation Limited China Merchants Bank Co., Ltd. Bank of Ningbo Co., Ltd JPMorgan Chase Bank Agricultural Bank of China
http://www.irasia.com/listco/hk/alihealth/ BUSINESS REVIEW
In the field of prescription drugs, the Group’s pharmaceutical direct sales business continued to deepen its collaboration with hundreds of pharmaceutical companies. By leveraging Alibaba Health’s digital advantages and through its global ecological operation system, the Group has organized special events and activities highlighting certain disease...
During the Reporting Period, the Group’s proprietary “Ma Shang Fang Xin”^ ( 碼上放心) tracking platform business continued to maintain a steady pace of development. In terms of its drug tracking services, the “Ma Shang Fang Xin” platform has further advanced its whole-value-chain coverage over drug production, distribution, retail terminal pharmacies a...
Alibaba Health has, together with Alibaba Foundation, launched the “Join Us for Training on Yi Die Gu”^ (醫蝶谷一起學) training program. The Group has also collaborated with China Association of County Hospital President, Beijing Ling Feng Foundation and The Red Cross Society of China to provide free access to medical knowledge and skill training for gra...
Alibaba Health will continue to uphold the value of longtermism, adhere to its objective of providing healthcare services through the Internet, and place user value as its priority. By utilizing the Internet, Alibaba Health will work closely with its partners from the Alibaba ecosystem and other technological innovation means as it pushes for healt...
The Group’s operations and transactions are primarily located in the PRC. The Group has been prudent in managing its treasury functions and has maintained a healthy liquidity position throughout the Reporting Period. The board (the “Board”) of directors (the “Directors”) of Alibaba Health closely monitors the Group’s liquidity position to ensure th...
Except for certain bank balances and cash, most of the Group’s bank balances and cash are fixed deposits denominated in Hong Kong dollars, Renminbi and United States dollars, while other assets and liabilities are mainly denominated in either Hong Kong dollars or Renminbi. The Group does not have a foreign exchange hedging policy, but its managemen...
The Directors during the Reporting Period and up to the date of this report were:
Mr. ZHU Shunyan (Chairman and Chief Executive Officer) Mr. SHEN Difan Mr. TU Yanwu
Mr. LUO Tong Mr. WONG King On, Samuel Ms. HUANG Yi Fei (Vanessa)
Number of ordinary shares and underlying shares held, capacity and nature of interest Approximate percentage of the
During the Reporting Period, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company’s listed securities.
The Company has adopted its own code for securities transactions by the (i) Directors; and (ii) certain officers and employees of the Company or its subsidiaries that are considered to be likely in possession of unpublished inside information in relation to the Company or its securities, on terms not less exacting than those in the Model Code. In r...
The non-current asset information above is based on the locations of the assets and excludes deferred tax assets, an equity investment designated at fair value through other comprehensive income, financial assets at fair value through profit or loss and non-current receivables.
Bank interest income Government grants Foreign exchange differences, net Management fee income from a joint venture Other interest income Dividend income from financial assets at fair value through profit or loss Others
Fair value gain on financial assets at fair value through profit or loss, net Gain on deemed partial disposal of associates Gain on deregistration of subsidiaries Gain on recognition of net investment in a sublease Gain on disposal of items of property and equipment Total
The Group’s profit/(loss) before tax is arrived at after charging/(crediting):
Profit/(loss) attributable to ordinary equity holders of the parents used in the basic earnings/(loss) per share calculation
In addition to the transactions detailed elsewhere in this financial information, the Group had the following material transactions:
In addition to the outstanding balances detailed elsewhere in this financial information, the balances with related parties as at the end of the Reporting Period are listed below: The balances with fellow subsidiaries are unsecured, interest-free, and have no fixed terms of repayment.
The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:
The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:
The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:
The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:
其他人也問了
阿里健康(中國)於公司A持有的權益被攤薄至多少?
阿里健康(中國)於安徽華人持有的權益被攤薄至多少?
阿里健康(香港)將於2022年3月31日止年度收取之激勵費用總額為多少?
阿里健康信息技術有限公司在哪裡註冊成立?
阿里健康信息技術有限公司. (於百慕達註冊成立之有限公司) (股份代號:00241) 截至2021 年3 月31日止年度全年業績公告. 阿里健康信息技術有限公司(「本公司」或「阿里健康」)董事(「董事」)會(「董事會」)欣然公佈本公司及其附屬公司(統稱「本集團」)截至2021 年3 月31日止年度(「報告期」)之經審核年度業績,連同上個財政年度的比較數字。 本公司審核委員會(「審核委員會」)已審閱年度綜合財務報表。 摘要. 報告期內,本集團錄得收入人民幣15,518.5 百萬元,毛利人民幣3,617.2百萬元,同比分別增長61.7% 和62.1%。 收入和毛利的高速增長反映了本報告期內醫藥電商平台業務及醫藥自營業務的強勁表現。
公司網站. http://www.irasia.com/listco/hk/alihealth/ 管理層討論與分析. 業務回顧. 回顧截至2022 年9 月30 日止六個月(「報告期」),疫情防控逐漸趨於常態化,互聯網醫療和數字技術進一步發揮積極作用。 2022 年5月,中華人民共和國(「中國」)國務院辦公廳印發的《「十四五」國民健康規劃》,明確提出加快全民衞生健康信息化建設,推進信息互聯互通,推動互聯網醫院、互聯網+ 慢性病管理等建設。 2022 年6月,中國國家衞生健康委員會印發的《互聯網診療監管細則(試行)》,進一步對互聯網診療規範發展提供了新的指引。 2022 年9月,國家市場監督管理總局印發的《藥品網絡銷售監督管理辦法》,為醫藥電商行業高質量發展提供更加明確的要求。
- 母公司普通股權持有人應佔每股盈利╱（虧損）
02 阿里健康信息技術有限公司 二零二二年環境、社會及管治報告 關於本報告 發佈週期 本報告為年度報告，是阿里健康信息技術有限公司連續發佈的第六份環境、社會及管治報告。編製依據 本報告基於香港聯交所「上市規則指引」—附錄二十七《環境、社會及管治報告指引（》 HKEX-ESG）編製。
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED. 阿里健康信息技術有限公司. (於百慕達註冊成立之有限公司) (股份代號:00241) 截至2023 年3 月31日止年度全年業績公告. 阿里健康信息技術有限公司(「本公司」或「阿里健康」)董事(「董事」)會(「董事會」)欣然公佈本公司及其附屬公司(統稱「本集團」)截至2023 年3 月31日止年度(「報告期」)之經審核年度業績,連同上個財政年度(「同期」)的比較數字。 本公司審核委員會(「審核委員會」)已審閱年度綜合財務報表。 摘要.
